

Meningococcal Vaccines–Routine Risk

MenACWY (MCV4) and MenB vaccines each protect against different serogroups. They may be given at the same visit.

For **HIGH-RISK POPULATIONS** (increased exposure to meningococcal disease, HIV infection, complement deficiencies or asplenia), see recommendations at EZIZ.org/assets/docs/IMM-1218.pdf

Routine	As needed to provide short-term protection against most strains of serogroup B meningococcal disease
<p>All 11-12 years^{1,2}</p> 	<p>16-23 years (Preferred age is 16–18 years)</p> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> <p>1st dose</p>  </div> <div style="text-align: center;"> <p>1 month</p>  </div> <div style="text-align: center;"> <p>2nd dose</p>  </div> </div> <div style="border: 1px solid black; padding: 5px; margin: 10px auto; width: fit-content;"> <p>Use the same brand of MenB vaccine for each dose in the series.</p> </div> <p style="text-align: center;">— OR —</p> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> <p>1st dose</p>  </div> <div style="text-align: center;"> <p>6 months^{4,5}</p>  </div> <div style="text-align: center;"> <p>2nd dose^{4,5}</p>  </div> </div>
<p>All 16 years^{2,3}</p> <p>Booster dose</p> 	
<p>Catch-up for first-year college students 19–21 years of age if</p> <ul style="list-style-type: none"> • No prior vaccination OR • Received 1st dose when younger than 16 years 	

Notes:

1. HIV-infected persons are recommended to receive 2 MenACWY (MCV4) doses, 2 months apart as the primary series if not yet immunized before age 11-12 years.
2. MenACWY (MCV4) vaccines protect against serogroups A, C, W-135, and Y.
3. If the first dose of MenACWY (MCV4) is given at age 16 years, no booster dose is needed.
4. A two-dose series is recommended for persons who are not at increased risk for meningococcal disease. A three-dose (0, 1-2, and 6 months) series is recommended for persons at increased risk, including during outbreaks of serogroup B disease: see EZIZ.org/assets/docs/IMM-1218.pdf.
5. If the second dose was given at an interval of less than 6 months, a third dose should be given at least 6 months after the first dose.



California Department of Public Health,
Immunization Branch
This publication was supported by Grant
Number H23/CCH922507 from the Centers
for Disease Control and Prevention (CDC)